Cost-effectiveness and return on investment of hepatitis C virus elimination in China: A modelling study

Cost-effectiveness and return on investment of hepatitis C virus elimination in China: A modelling study

Background/Aims The World Health Organization set the goal of eliminating hepatitis C virus (HCV) by 2030, with 80% and 65% reductions in HCV incidence and mortality rates, respectively. We aimed to evaluate the health benefits, cost-effectiveness and return on investment (ROI) of HCV elimination. M...

Full description

Saved in:

Bibliographic Details
Main Authors:	Meiyu Wu, Jing Ma, Xuehong Wang, Sini Li, Chongqing Tan, Ouyang Xie, Andong Li, Aaron G Lim, Xiaomin Wan
Format:	Article
Language:	English
Published:	Korean Association for the Study of the Liver 2025-04-01
Series:	Clinical and Molecular Hepatology
Subjects:	hepatitis c disease eradication cost-effectiveness analysis outcome assessment, health care china
Online Access:	http://e-cmh.org/upload/pdf/cmh-2024-0664.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Viral hepatitis: a review of global prevalence and research progress toward elimination
by: Wenqi HUANG, et al.
Published: (2024-11-01)

The macroeconomic burden of hepatitis C and the economic benefit of accelerated investments in China
by: Yun Bao, et al.
Published: (2025-05-01)

Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiveness
by: Gyeongseon Shin, et al.
Published: (2025-01-01)

Universal self-testing as a cost-effective weapon to eliminate hepatitis C virus in the Republic of Korea: Editorial on “Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiveness”
by: Eun Sun Jang
Published: (2025-04-01)

Eliminating malaria in Nigeria: insights from Egypt’s success and pathways to sustainable eradication
by: Stanley Chinedu Eneh, et al.
Published: (2025-06-01)

Estimated costs of plum pox virus and management of sharka, the disease it causes
by: Mariano CAMBRA, et al.
Published: (2024-11-01)

Stochastic population models to identify optimal and cost‐effective harvest strategies for feral pig eradication
by: Peter W. Hamnett, et al.
Published: (2024-12-01)

Malaria elimination: needs assessment and priorities for the future
by: Amal El-Moamly
Published: (2013-11-01)

Global challenges and solutions to achieving and sustaining measles and rubella elimination
by: Natasha S. Crowcroft, et al.
Published: (2024-12-01)

Efficacy and cost-effectiveness analysis of 10-day versus 14-day eradication of Helicobacter pylori infection with vonoprazan amoxicillin: a prospective, multicenter, randomized controlled trial
by: Yunfan Dong, et al.
Published: (2025-03-01)

Tailored Therapy Using Bismuth Add-on Standard Triple Therapy vs. Concomitant Therapy: A First-line Regimen for Helicobacter pylori Infection
by: Soo Yeon Choi, et al.
Published: (2023-06-01)

Long-term results of antiviral therapy in patients with chronic hepatitis C with sustained virologic response
by: T. M. Ignatova, et al.
Published: (2013-09-01)

Is it possible to eliminate or eradicate human fish-borne parasitic diseases? A sweet dream or a nightmare?
by: Jorge C. Eiras
Published: (2024-01-01)

Epidemiological trends of hepatitis in mainland China: 2004–2019
by: Si Chen, et al.
Published: (2025-08-01)

HCV self-testing: Bridging screening gaps and ensuring cost-effectiveness for both high-risk and universal populations: Correspondence to editorial on “Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiveness”
by: Gyeongseon Shin, et al.
Published: (2025-04-01)

Effectiveness and safety of vonoprazan and amoxicillin dual regimen with Saccharomyces boulardii supplements on eradication of Helicobacter pylori
by: Jing Yu, et al.
Published: (2024-11-01)

Cost-effectiveness of advanced hepatic fibrosis screening in individuals with suspected MASLD identified by serologic noninvasive tests
by: Huiyul Park, et al.
Published: (2025-07-01)

Probiotic Supplementation for Treatment of Infection: A Double-Blind Randomized Clinical Trial
by: Na Rae Lim, et al.
Published: (2023-03-01)

Toward elimination of hepatitis A and B in Europe: vaccination successes, challenges, and opportunities
by: Maria Buti, et al.
Published: (2025-12-01)

Regional and age related variations in hepatitis A virus incidence in China 2004 to 2018: a descriptive epidemiological study
by: Yan Xu, et al.
Published: (2025-06-01)

Cost-effectiveness of tenofovir disoproxil fumarate prophylaxis for perinatal hepatitis B virus prevention in Ethiopia: a decision analytical modeling
by: Abdi Gari Negasa, et al.
Published: (2025-04-01)

Epidemiological trends of hepatitis C incidence and death in Mainland China between 2004 and 2018 and its predictions to 2030
by: Guo Tian, et al.
Published: (2025-04-01)

Seroprevalence of hepatitis B surface antigen and hepatitis B e antigen among childbearing-age women in Mianyang, China
by: Min Wang, et al.
Published: (2015-07-01)

Navigating resistance in global health governance: Certification of smallpox eradication in China
by: Lu Chen
Published: (2024-12-01)

Cost-effectiveness of antiviral therapy in chronic hepatitis C (G1)
by: A. V. Rudakova, et al.
Published: (2016-02-01)

Hepatitis E virus: a foodborne pathogen of concern in China
by: Jiahui Wang, et al.
Published: (2025-07-01)

Cost-effectiveness of narlaprevir in the chronic hepatitis C (genotype 1) therapy in treatment-naïve patients and relapsers
by: D. A. Gusev, et al.
Published: (2016-11-01)

Molecular epidemiology of rubella during the pre- and post-elimination eras in the Americas
by: Min-hsin Chen, et al.
Published: (2024-12-01)

Cost-effectiveness analysis of a new paradigm to simplify testing, monitoring and treatment of hepatitis C virus in the United States
by: Douglas Dietrich, et al.
Published: (2025-06-01)

Preliminary investigation on the economic cost of mitochondrial disease in Chinese children
by: Chaolong Xu, et al.
Published: (2025-04-01)

REVIRAL: roadmap for the elimination of viral hepatitis in Latin America
by: Javier Crespo, et al.
Published: (2025-05-01)

Bureaucratic reform as an effort to prevent corruption in Indonesia
by: Dewi Asri Yustia, et al.
Published: (2023-12-01)

Legal Politics of Weakening The Corruption Eradication Commission
by: Sena kogam Muhammad Nur Vivananda Irsyad
Published: (2025-04-01)

Cost-effectiveness of antiviral therapy in treatment-naive patients with chronic hepatitis C (genotype 1)
by: A. V. Rudakova, et al.
Published: (2017-06-01)

Stakeholder perspectives and the challenges in implementing hepatitis C elimination policy in Pakistan
by: Naeem Asim, et al.
Published: (2025-07-01)

Approach to Patients after Successful Eradication of
by: Hee Seok Moon
Published: (2023-03-01)

Economic burden of hepatitis B patients and its influencing factors in China: a systematic review
by: Mengxia Yan, et al.
Published: (2024-11-01)

Estimated Costs and Returns of Hemp Flower Production
by: Trent Blare, et al.
Published: (2024-08-01)

Efficiency of ursodeoxycholic acid in the frameworks of minimization of hepatotoxic potential of eradication therapy of Helicobacter pylori infection
by: D. N. Andreev, et al.
Published: (2021-06-01)

Catastrophic costs of Tuberculosis in patients registered under the National Tuberculosis Elimination Programme in South-East Delhi, India
by: Tazean Zahoor Malik, et al.
Published: (2025-07-01)